As a result of recent advances in cancer immunotherapy, immune checkpoint inhibitors have achieved durable clinical responses in at least one-fifth of patients with various types of advanced cancer.[@b1]--[@b3] However, the clinical activity of immune checkpoint inhibitors was dependent on the presence of T lymphocytes at tumor sites. Therefore, clinical benefits could not be expected in cancer patients whose tumors had no or fewer tumor-infiltrating lymphocytes. Moreover, the clinical efficacy of chemotherapy with cytotoxic reagents has been well correlated with the number of tumor-infiltrating lymphocytes.[@b4] We previously reported that personalized peptide vaccination (PPV) rapidly induced proliferation of CD45RO^+^ activated lymphocytes at tumor sites in association with clinical benefits in patients with advanced prostate cancer or bladder cancer.[@b5]--[@b7] These results suggest that sequential cancer therapy consisting of PPV followed by either immune checkpoint inhibitors or chemotherapy with cytotoxic reagents could be more efficacious than monotherapy. Indeed, we recently reported that PPV followed by chemotherapy was associated with a favorable clinical outcome in refractory ovarian cancer patients.[@b8]

Although many clinical trials of peptide-based cancer vaccines for HLA-A2^+^ and HLA-A24^+^ cancer patients have been carried out in the past two decades, cancer patients with the other alleles, including HLA-A1, -A3, -A11, -A26, -A31, or -A33, were excluded from these clinical trials because of the relatively lower allele expression worldwide.[@b9],[@b10] To develop cancer vaccines applicable for these minor HLA-A alleles, we previously identified large numbers of CTL epitope peptides from alleles other than A2 or A24, and some of them were provided for the clinical trials of peptide vaccines for the HLA-A3 superfamily (HLA-A11, -A31, and -A33) or HLA-A26^+^ cancer patients under PPV regimens in the past 7 years.[@b11],[@b12] The HLA-A26 allele is found in approximately 11% of the Japanese population, 4% of the Caucasian population in the USA, and 7.5% of the African population of Cape Town.[@b10]

In this study, we retrospectively analyzed the results of PPV for HLA-A26^+^/A26^+^ advanced cancer patients from the various regimens of PPV carried out in the past 7 years to investigate the feasibility of using PPV for HLA-A26^+^/A26^+^ advanced cancer patients from the viewpoints of safety and immunological responses.

Patients and Methods
====================

Peptides
--------

The four different CTL epitope peptides used in this study were SART3~109--118~ VYDYNCHVDL, ppMAPkkk~432--440~ DLLSHAFFA, HNRPL~501--510~ NVLHFFNAPL, and WHSC2~103--111~ ASLDSDPWV peptides. All were previously shown to be capable of inducing peptide-specific and tumor-reactive CTL activity in HLA-A26 cancer patients.[@b10] These peptides were prepared under the conditions of Good Manufacturing Practice by the PolyPeptide Laboratories (San Diego, CA, USA) and American Peptide Company (Vista, CA, USA), as reported previously.[@b7],[@b13]--[@b18]

Patients
--------

Patients diagnosed with cancer were eligible for this study. They had to show positive IgG responses to at least two of the four peptide candidates applicable for HLA-A26^+^ cancer patients. Other inclusion criteria were as follows: age between 20 and 80 years; an Eastern Cooperative Oncology Group performance status of 0 or 1 at the time of first visit; life expectancy of at least 12 weeks; and adequate hematologic, hepatic, and renal function. Exclusion criteria included: pulmonary, cardiac, or other systemic diseases; an acute infection; a history of severe allergic reactions; pregnancy or nursing; and other inappropriate conditions for enrolment as judged by clinicians. The protocol was approved by the Kurume University (Kurume, Japan) Ethical Committee and registered with the UMIN Clinical Trials Registry (UMIN nos. 1482, 1839, 1844, 1850, 1854--1856, 1881--1883, 2908, 2984, 2987, 6493, and 10068). All patients were given a full explanation of the protocol and provided their informed consent before enrolment.

Clinical protocol
-----------------

This was a phase II study to evaluate the safety, immunological responses, and clinical benefits from the viewpoint of overall survival in heavily treated cancer patients under PPV. Peptides for vaccination to individual patients were selected in consideration of the pre-existing host immunity before vaccination, as assessed by the titers of IgG specific to each of the four different vaccine candidates.[@b7],[@b11],[@b12],[@b16]--[@b18] A maximum of four peptides (3 mg/each peptide), which were selected based on the results of HLA typing and peptide-specific IgG titers, were s.c. administered with incomplete Freund's adjuvant (Montanide ISA51; Seppic, Paris, France) once a week for 6 consecutive weeks (UMIN nos. 1482, 1839, 1844, 1850, 1854--1856, 1881--1883, 6493, and 10068), or once a week for 4 consecutive weeks followed by four biweekly treatments (UMIN nos. 2908, 2984, and 2987) as the first cycle. After the first cycle of vaccinations, up to four antigen peptides that were reselected according to the titers of peptide-specific IgG were given six or eight times on a biweekly basis. After the first cycle of vaccinations, up to four antigen peptides that were reselected again were given every 4 weeks until the 24th vaccination. During the PPV, patients were allowed to receive combination therapies, such as chemotherapies or radiotherapies. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Complete blood counts and serum biochemistry tests were carried out before and after each cycle of vaccinations. Tumor assessments by computed tomography or MRI scans were carried out before and after PPV, and evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1.

Laboratory markers
------------------

Humoral immune responses specific to each of the four peptide candidates were determined by peptide-specific IgG levels using the Luminex system (Luminex, Austin, TX, USA), as previously reported.[@b19]--[@b22] If the titers of peptide-specific IgG to at least one of the vaccinated peptides at the end of the first cycle were more than twofold higher than those in the prevaccination plasma, the changes were considered to be significant, as previously reported. The CTL responses specific to the vaccinated peptides were evaluated by γ-interferon ELISPOT assays using PBMCs before and at the end of the first cycle, as previously reported.[@b19]--[@b22]

Cell surface markers and cytokines
----------------------------------

As cell surface markers, myeloid-derived suppressor cells (CD33, CD11b, CD14, CD15, CD3, CD16, CD19, CD56, and HLA-DR), regulatory T cells (CD4, CD25, and FoxP3), BTLA, PD-1, CTLA-4, and LAG-3 were measured by a BD FACSCanto II System with FACS Diva software (BD Biosciences, San Diego, CA, USA). In addition, the levels of interleukin (IL)6, IL8, and γ-interferon-induced protein 10 (IP-10) in plasma before and after one cycle of vaccination were examined by ELISA using kits from eBioscience (San Diego, CA, USA), as reported previously.[@b23]

Statistical analyses
--------------------

All data were analyzed retrospectively. Comparison of each group was carried out using [anova]{.smallcaps}. Overall survival was calculated from the first day of peptide vaccination until the date of death or the last date when the patient was known to be alive. Values of *P *\< 0.05 were considered to indicate statistical significance. All statistical analyses were carried out using JMP software, version 12 (SAS Institute, Cary, NC, USA).

Results
=======

Patients' characteristics
-------------------------

Between December 2008 and August 2014, 21 A26^+^/A26^+^ advanced cancer patients were enrolled to this study. Their genotypes were A26:01 (*n* = 24), HLA-A26:03 (*n* = 10), and HLA-A26:02 (*n* = 8). Their diagnosis was lung cancer (*n* = 7), breast cancer (*n* = 3), pancreatic cancer (*n* = 2), colon cancer (*n* = 2), and one case each of prostate cancer, stomach cancer, liver cancer, kidney cancer, bladder cancer, uterine cancer, and ovarian cancer. The patients' characteristics are shown in Table[1](#tbl1){ref-type="table"}. The median age was 65 years (range, 46--75 years). The median lymphocyte number at the time of enrolment was 1600/mm^3^ (range, 1004--2035/mm^3^). Performance status at the time of enrolment was grade 0 (*n* = 18) or grade 1 (*n* = 3). The numbers of previous chemotherapy regimens were one (*n* = 8), two (*n* = 2), three (*n* = 4), and more than three (*n* = 4). Fifteen patients received combined chemotherapy or other therapy such as hormone therapy along with PPV. Sixteen patients completed the first cycle of vaccinations, whereas the remaining five patients did not due to rapid disease progression. The median number of vaccinations was 12 (range, 1--32).

###### 

Characteristics of HLA-A26^+^/A26^+^ cancer patients (*n* = 21) treated with personalized peptide vaccine regimens

  No.   HLA-A genotype   Primary   Pathology   Age, years                    Gender   Stage   No. of lymphocytes   PS     Previous chemotherapy   Previous other therapy[†](#tf1-1){ref-type="table-fn"}   Combined chemotherapy   Combined other therapy[†](#tf1-1){ref-type="table-fn"}   No. of vaccinations   Overall survival   Clinical response at 3 months after first vaccination                                                         
  ----- ---------------- --------- ----------- ----------------------------- -------- ------- -------------------- ------ ----------------------- -------------------------------------------------------- ----------------------- -------------------------------------------------------- --------------------- ------------------ ------------------------------------------------------- ---- ---- ---- -------------------------------------- ---------
  1     26:01            26:03     Lung        Small cell carcinoma          70       M       IV                   2035   1                       1                                                        −                       \+                                                       −                     1                  \+                                                      −    −    4    70                                     Death
  2     26:01            26:03     Lung        Squamous cell carcinoma       65       M       IV                   1180   0                       1                                                        −                       \+                                                       \+                    1                  \+                                                      −    −    4    80                                     Death
  3     26:01            26:03     Lung        Adenocarcinoma                72       M       Rec.                 1034   0                       0                                                        −                       −                                                        \+                    0                  −                                                       −    −    17   435[‡](#tf1-2){ref-type="table-fn"}    SD
  4     26:01            26:03     Lung        Adenocarcinoma                56       F       Rec.                 1134   0                       3                                                        \+                      −                                                        −                     2                  \+                                                      −    −    24   692                                    SD
  5     26:01            26:03     Lung        Adenocarcinoma                70       M       III                  1007   0                       1                                                        \+                      −                                                        \+                    0                  −                                                       −    −    13   312[‡](#tf1-2){ref-type="table-fn"}    SD
  6     26:01                      Lung        Adenocarcinoma                75       M       Rec.                 1189   0                       3                                                        \+                      −                                                        −                     3                  \+                                                      \+   −    17   367                                    SD
  7     26:01            26:02     Lung        Adenocarcinoma                69       M       IV                   1005   0                       3                                                        \+                      \+                                                       −                     2                  \+                                                      \+   −    3    47[‡](#tf1-2){ref-type="table-fn"}     Unknown
  8     26:01                      Breast      Invasive ductal carcinoma     55       F       Rec.                 1004   0                       2                                                        \+                      −                                                        −                     2                  \+                                                      −    −    9    381                                    PD
  9     26:01                      Breast      Invasive ductal carcinoma     68       F       IV                   1550   1                       6                                                        \+                      −                                                        −                     0                  −                                                       −    −    1    20                                     Death
  10    26:03                      Breast      Mucinous carcinoma            55       F       Rec.                 1390   0                       3                                                        \+                      \+                                                       \+                    0                  −                                                       −    \+   18   703[‡](#tf1-2){ref-type="table-fn"}    SD
  11    26:01            26:03     Pancreas    Adenocarcinoma                74       M       I                    2011   0                       0                                                        −                       −                                                        −                     0                  −                                                       −    −    32   1058[‡](#tf1-2){ref-type="table-fn"}   SD
  12    26:02                      Pancreas    Adenocarcinoma                64       M       IV                   1803   0                       1                                                        \+                      −                                                        −                     1                  \+                                                      −    −    6    74                                     Death
  13    26:01            26:02     Colon       Adenocarcinoma                60       M       IV                   1365   0                       4                                                        \+                      \+                                                       \+                    0                  −                                                       −    −    4    54                                     Death
  14    26:01                      Colon       Adenocarcinoma                51       F       Rec.                 1282   0                       5                                                        \+                      \+                                                       \-                    2                  \+                                                      \+   −    9    202                                    SD
  15    26:01            26:03     Prostate    Adenocarcinoma                62       M       IV                   1492   0                       1                                                        −                       \+                                                       \+                    2                  \+                                                      −    \+   30   949                                    SD
  16    26:01                      Stomach     Adenocarcinoma                70       M       IV                   1200   0                       0                                                        −                       −                                                        −                     1                  \+                                                      −    −    12   701[‡](#tf1-2){ref-type="table-fn"}    SD
  17    26:01            26:03     Liver       Hepatocellualar carcinoma     46       M       IV                   1050   0                       4                                                        \+                      \+                                                       \+                    1                  −                                                       \+   −    6    209                                    SD
  18    26:01                      Kidney      Clear cell type               53       M       Rec.                 1673   0                       1                                                        −                       \+                                                       −                     1                  −                                                       \+   −    9    1820                                   SD
  19    26:02                      Bladder     Transitional cell carcinoma   66       M       Rec.                 1612   0                       1                                                        \+                      −                                                        −                     1                  \+                                                      −    −    12   346[‡](#tf1-2){ref-type="table-fn"}    PD
  20    26:01            26:02     Uterus      Leiomyosarcoma                52       F       Rec.                 1430   0                       1                                                        \+                      −                                                        −                     1                  \+                                                      −    −    12   489                                    SD
  21    26:01            26:02     Oval        Adenocarcinoma                65       F       Rec.                 1300   1                       2                                                        \+                      \+                                                       −                     0                  −                                                       −    −    18   642[‡](#tf1-2){ref-type="table-fn"}    SD

Other therapy included radiation therapy, hormone therapy and intra-arterial injection therapy.

Patients are alive. +, Used; −, not used; F, female; M, male; NA, not assessed; OS, overall survival; PD, progression desease; PS, performance status; Rec., Recurrence; SD, stable disease.

Adverse events
--------------

Table[2](#tbl2){ref-type="table"} shows the adverse events during the PPV. Grade 1 or 2 injection site reactions were observed in 15 of 21 (71.4%) patients. Severe adverse events were seen in four patients (grade 3, two neutropenia and one hypertension; grade 4, one neutropenia). All of them were concluded to be not directly associated with the PPV, but with disease progression or combined therapy according to evaluation by the independent safety evaluation committee.

###### 

Adverse events in HLA-A26^+^/A26^+^ cancer patients (*n* = 21) treated with personalized peptide vaccine regimens

                                          Grade 1   Grade 2   Grade 3   Grade 4                 
  --------------------------------------- --------- --------- --------- --------- --- ----- --- -----
  Injected site reaction                  8         38.1      7         33.3      0   0.0   0   0.0
  General disorder                                                                              
  Fever                                   0         0.0       1         4.8       0   0.0   0   0.0
  Blood/bone marrow                                                                             
  Anemia                                  0         0.0       3         14.3      0   0.0   0   0.0
  Leukopenia                              0         0.0       0         0.0       0   0.0   0   0.0
  Neutropenia                             0         0.0       1         4.8       2   9.5   1   4.8
  Lympocytopenia                          1         4.8       3         14.3      0   0.0   0   0.0
  Thrombocytopenia                        1         4.8       0         0.0       0   0.0   0   0.0
  Metabolic and laboratory                                                                      
  AST increased                           3         14.3      0         0.0       0   0.0   0   0.0
  ALT increased                           1         4.8       2         9.5       0   0.0   0   0.0
  γ-GTP increased                         4         19        0         0.0       0   0.0   0   0.0
  ALP increased                           0         0.0       0         0.0       0   0.0   0   0.0
  Hypoalbuminemia                         7         33.3      2         9.5       0   0.0   0   0.0
  Creatinine increased                    1         4.8       0         0.0       0   0.0   0   0.0
  Electrolyte imbalance                   0         0.0       1         4.8       0   0.0   0   0.0
  Neurological                                                                                  
  Tumor pain                              2         9.5       1         4.8       0   0.0   0   0.0
  Vascular disorder                       0         0.0       0         0.0       0   0.0   0   0.0
  Hypertension                            0         0.0       0         0.0       1   4.8   0   0.0
  Gastrointestinal disorder                                                                     
  Diarrhea                                0         0.0       1         4.8       0   0.0   0   0.0
  Skin and subcutaneous tissue disorder                                                         
  Alopecia                                0         0.0       1         4.8       0   0.0   0   0.0
  Rash acneiform                          1         4.8       0         0.0       0   0.0   0   0.0

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GTP, γ-glutamyl transpeptidase.

Immune responses
----------------

Both peptide-specific CTL and IgG responses were analyzed in blood samples from 21, 16, and 11 patients before vaccinations, after the first cycle of vaccinations, and after the second cycle of vaccinations, respectively. Peptide-specific IgG reactive to each of the 31 different peptides, including both the vaccinated and non-vaccinated peptides, were measured by the Luminex system. The numbers of peptides used for the first cycle of vaccinations were two, three, and four in 1, 14, and 6 patients, respectively. The IgG responses before vaccination were observed in all the patients. The IgG responses specific to at least one of the vaccinated peptides were increased after the first cycle of vaccination in 11 of 16 (69%) patients tested, and after the second cycle of vaccination in all 11 patients tested (Table[3](#tbl3){ref-type="table"}).

###### 

Immune responses after first and second cycles of personalized peptide vaccination

  Patient no.    Peptide        IgG responses to vaccinated peptide[†](#tf3-1){ref-type="table-fn"}   CTL response[‡](#tf3-2){ref-type="table-fn"}                        
  -------------- -------------- --------------------------------------------------------------------- ---------------------------------------------- -------- ----- ----- ----
  3              SART3-109      60                                                                    43                                             4625     0     0     0
  ppMAPkkk-432   103            96                                                                    868                                            0        554   0     
  WHSC2-103      19             16                                                                    31                                             238      0     0     
  4              SART3-109      ND                                                                    ND                                             746      NA    NA    NA
  ppMAPkkk-432   353            319                                                                   281                                            NA       NA    NA    
  HNRPL-501      122            124                                                                   30 500                                         NA       NA    NA    
  WHSC2-103      229            217                                                                   729                                            NA       NA    NA    
  5              ppMAPkkk-432   ND                                                                    25                                             16       0     0     0
  HNRPL-501      172            197                                                                   1530                                           0        0     0     
  WHSC2-103      4115           2460                                                                  1869                                           0        0     0     
  6              SART3-109      21                                                                    55                                             21 478   NA    NA    NA
  HNRPL-501      13             23                                                                    7715                                           NA       NA    NA    
  WHSC2-103      ND             ND                                                                    12                                             NA       NA    NA    
  8              SART3-109      109                                                                   110                                            NA       200   0     NA
  HNRPL-501      62             51                                                                    NA                                             149      0     NA    
  WHSC2-103      24             22                                                                    NA                                             0        0     NA    
  10             SART3-109      ND                                                                    ND                                             388      NA    NA    0
  ppMAPkkk-432   ND             ND                                                                    55                                             NA       NA    0     
  HNRPL-501      17             185                                                                   27 281                                         0        722   0     
  WHSC2-103      34             42                                                                    119                                            0        0     0     
  11             SART3-109      23                                                                    20                                             9540     0     0     0
  ppMAPkkk-432   ND             11                                                                    11                                             0        0     0     
  HNRPL-501      ND             ND                                                                    10                                             0        0     0     
  WHSC2-103      22             14405                                                                 5951                                           0        0     0     
  12             SART3-109      76                                                                    76                                             NA       0     0     NA
  ppMAPkkk-432   86             94                                                                    NA                                             0        0     NA    
  HNRPL-501      43             39                                                                    NA                                             0        0     NA    
  WHSC2-103      642            654                                                                   NA                                             0        0     NA    
  14             SART3-109      18                                                                    8432                                           NA       0     0     NA
  HNRPL-501      253            21 599                                                                NA                                             0        0     NA    
  WHSC2-103      14             43                                                                    NA                                             0        0     NA    
  15             SART3-109      69                                                                    210                                            8276     0     0     0
  ppMAPkkk-432   141            144                                                                   18 124                                         0        223   816   
  WHSC2-103      82             ND                                                                    10 876                                         0        0     0     
  16             SART3-109      23                                                                    ND                                             20 743   0     0     0
  WHSC2-103      42             112                                                                   7474                                           0        0     0     
  17             SART3-109      132                                                                   ND                                             NA       NA    NA    NA
  ppMAPkkk-432   200            ND                                                                    NA                                             NA       NA    NA    
  HNRPL-501      146            ND                                                                    NA                                             NA       NA    NA    
  18             SART3-109      2930                                                                  12 149                                         NA       359   132   NA
  ppMAPkkk-432   15             16                                                                    NA                                             0        0     NA    
  HNRPL-501      454            473                                                                   NA                                             0        0     NA    
  19             SART3-109      29                                                                    280                                            25 446   0     0     0
  ppMAPkkk-432   248            290                                                                   36 864                                         0        0     486   
  HNRPL-501      ND             11                                                                    7523                                           0        0     0     
  WHSC2-103      3086           2906                                                                  2847                                           0        0     0     
  20             SART3-109      11                                                                    16                                             23 089   0     0     0
  ppMAPkkk-432   15             21                                                                    41                                             0        0     0     
  HNRPL-501      ND             ND                                                                    24                                             0        0     0     
  21             ppMAPkkk-432   62                                                                    87                                             134      0     0     0
  HNRPL-501      18             38 589                                                                36 619                                         0        0     0     
  WHSC2-103      23             66                                                                    1877                                           0        342   0     

If the titers of peptide-specific IgG at the end of the first or second cycles were more than twofold higher than those in the prevaccination plasma, or were newly appeared, these changes were considered to be enhanced. The augmented IgG responses are underlined.

CTL responses were determined by the number of spots per 10^5^ PBMCs reactive with the vaccinated peptides in γ-interferon ELISPOT assay before and after the first or second cycles of vaccination. The augmented T cell responses are underlined. NA, not assessed; ND, not detected.

The CTL responses to the vaccinated peptides before vaccination were detectable in 3 of 13 (23%) patients (Table[3](#tbl3){ref-type="table"}). They became detectable after the first cycle of vaccination in 5 of 13 (38%) patients and after the second cycle of vaccination in 2 of 9 (22%) patients.

Collectively, after the first cycle of vaccination, 3 patients showed both increased CTL and IgG responses to the vaccinated peptides, 11 of 16 patients showed either increased CTL or IgG responses, and the remaining 5 patients showed neither CTL nor IgG boosting. All 11 patients showed either increased CTL or IgG responses to the vaccinated peptides after the second cycle of vaccination.

Cell surface marker and inflammatory cytokines
----------------------------------------------

We also measured immune cell subsets in pre- and post-vaccination (after the first cycle) of PBMCs, including myeloid-derived suppressor cells, regulatory T cells, or BTLA-, PD-1-, CTLA-4-, and LAG-3-postive cells, by flow cytometry. In addition, we measured pre- and post-vaccination (after the first cycle) of plasma levels of cytokines, including IL6, IL8, and IP-10. Neither the immune cell subsets nor the cytokine levels in prevaccination samples were significantly different from those of the post-vaccination samples (Table[4](#tbl4){ref-type="table"}).

###### 

Cell surface markers and cytokines before and after one cycle of personal peptide vaccine[†](#tf4-1){ref-type="table-fn"}

                                          Before               After 1 cycle        *P*-value[‡](#tf4-2){ref-type="table-fn"}
  --------------------------------------- -------------------- -------------------- -------------------------------------------
  MDSCs, %lymphocytes                     0.84 (0.25--1.70)    0.96 (0.67--2.13)    0.48
  Regulatory T cells, %lymphocytes        1.33 (0.55--2.97)    1.54 (0.90--3.17)    0.23
  BTLA^+^CD4^+^ T cells, %lymphocytes     29.9 (15.8--54.8)    31.4 (20.1--44.8)    0.51
  BTLA^+^CD8^+^ T cells, %lymphocytes     13.6 (7.9--21.2)     14.2 (8.0--24.5)     0.56
  PD-1^+^CD4^+^ T cells, %lymphocytes     1.37 (0.45--2.54)    1.63 (0.40--3.38)    0.13
  PD-1^+^CD8^+^ T cells, %lymphocytes     0.56 (0.25--1.01)    0.47 (0.17--0.93)    0.06
  CTLA-4^+^CD4^+^ T cells, %lymphocytes   0.05 (0.02--0.16)    0.06 (0.02--0.13)    0.65
  CTLA-4^+^CD8^+^ T cells, %lymphocytes   15.1 (7.4--27.3)     16.0 (11.6--25.9)    0.57
  LAG-3^+^CD4^+^ T cells, %lymphocytes    0.18 (0.03--0.53)    0.23 (0.06--0.47)    0.28
  LAG-3^+^CD8^+^ T cells, %lymphocytes    0.43 (0.06--1.58)    0.45 (0.10--1.33)    0.58
  IL6, pg/mL                              9.88 (5.30--37.67)   7.76 (5.15--17.71)   0.24
  IL8, pg/mL                              22.2 (1.8--86.6)     26.1 (2.2--149.8)    0.79
  IP--10, pg/mL                           150 (63--354)        172 (110--412)       0.45

Eleven of 16 patients who ended one cycle of treatment with personal peptide vaccine were measured. Five patients could not be measured because their samples were insufficient.

Paired *t*-test was used to examine *P*-values. IL, interleukin; IP-10, γ-interferon-induced protein 10; MDSCs, myeloid-derived suppressor cells.

Clinical response
-----------------

Best clinical responses were evaluated by radiological findings. There were no cases of complete response, no cases of partial response, 13 cases of stable disease (SD), and 7 cases of progressive disease (PD) (Table[1](#tbl1){ref-type="table"}). Computed tomography findings of 1 patient of SD case before vaccination and after 2 cycles of vaccination are shown in Figure[1](#fig01){ref-type="fig"}. This case (case \#3 in Table[1](#tbl1){ref-type="table"}) was a 72-year-old man with recurrent lung cancer after radiation therapy treated with PPV alone. At 1 year after the 1^st^ vaccination, the tumor had grown slightly, but showed stable disease (SD). Both the cellular immune responses and IgG responses to vaccinated peptides were well boosted in this case (case \#3 in Table[3](#tbl3){ref-type="table"}).

![Clinical responses to personalized peptide vaccination (PPV). Computed tomography findings of a patient with stable disease. (a) At diagnosis of lung cancer, 1 year before first vaccination. (b) At recurrence of lung cancer, 3 months before first vaccination. Before this time, the patient had undergone radiation therapy and achieved complete response. (c) One year after first vaccination, the tumor had increased slightly, but stable disease was maintained. Arrows indicate tumur site.](cas0106-1257-f1){#fig01}

Discussion
==========

To the best of our knowledge, this is the first clinical trial of peptide-based cancer vaccines for HLA-A26^+^ cancer patients. The HLA-A26 allele is found in approximately 11% of the Japanese population and includes various genotypes.[@b10] The frequencies of the different HLA-A26 genotypes in the Japanese population have been reported as follows: HLA-A2601: 7.35%; HLA-A2603: 2.23%; HLA-A2603: 1.81%; HLA-A2605: 0.07%; and HLA-A2606: 0.01%.[@b24] Their HLA-A26 genotypes of the 21 patients in this study were HLA-A26:01 (*n* = 24), HLA-A26:03 (*n* = 10), and HLA-A26:02 (*n* = 8). Thus the trend among the present patient population was similar to that for Japan as a whole, although it is difficult to compare the two sets of results because of the extremely small size of our subject group (21 patients).

From the viewpoint of adverse events, a grade 1 or 2 injection site reaction was observed in 70% of the patients. Severe adverse events were seen in 4 patients, and all of them were concluded to be not directly associated with the PPV, but with the disease progression or combined therapy. These results were consistent with the previous results on PPV for the HLA-A24^+^ or -A2^+^ cancer patients reported previously.[@b11],[@b12]

This study showed the successful boosting of HLA-A26 restricted peptide-specific immune responses in blood samples after the 6th vaccination of PPV. Boosting for peptide-specific IgG responses, which were clearly detectable in all 21 patients, was especially apparent in 63% or 100% of patients after the 1st cycle or 2nd cycle of vaccination, respectively. We have reported that boosting of IgG responses is well correlated with overall survival.[@b21],[@b25]

In contrast to IgG responses, peptide-specific CTL responses of each of the vaccine candidates were rarely detectable. There were several possible explanation for this discrepancy between IgG and CTL boosting. One of them could be deletion or depression of the expression of HLA-A26 molecules on the surface of cancer cells from these HLA-A26 homogenous advanced cancer patients. PBMCs from HLA-A26 heterogeneous advanced cancer patients were provided for *in vitro* determination of these 4 peptides that could induce peptide-specific CTL activity for HLA-A26^+^ cancer patients as reported previously.[@b10] Their clinical stages were not as advanced as to those of the 21 patients who received PPV in this study. The other explanation could be that the numbers of pooled peptides were too small to correspond to antigenic heterogeneity of tumor cells and also diverse immune responses among cancer patients. Indeed, 9 of 30 (30%) HLA-A26^+^/A26^+^ cancer patients could not be enrolled in this study because they did not have more than 2 positive IgG responses among the 4 pooled peptides. Therefore, the development of additional HLA-A26 restricted peptides is needed. In addition, if patients have both the HLA-A2, -A24, or A3 superfamily and HLA-A26, it might be appropriate to use both the peptides matched with the HLA-A2, -A24, or A3 superfamily and those matched with the HLA-A26 allele, as we have been conducting the vaccination using both the peptides with the successful boosting of peptide-specific CTL responses as reported previously.[@b11],[@b12],[@b21],[@b23]

This was a small study with a limited number of patients for investigation of the PPV-induced immunological responses in HLA-A26^+^/A26^+^ cancer patients. Therefore, clinical benefits were not set as the secondary objective. However, it could be important to provide available information on the clinical outcome of these patients under PPV. We have previously reported the possibility of extending the overall survival in clinical trials of PPV in each organ cancer patients, and especially for patients who exhibit humoral responses and T cell responses. As a result, there were no complete response, no partial response, 13 stable disease (SD), 7 progressive disease, and 1 unknown. Five patients (one each with stage IV small-cell lung cancer, adenocarcinoma lung cancer, invasive ductal breast cancer, pancreatic cancer, and colon cancer patients) could not receive the first cycle of vaccination because of rapid disease progression and died within 80 days of the first vaccination. The other 16 patients received at least six vaccinations (median, 15 vaccinations; range, 3--32 vaccinations), and their median survival time was 949 days (range, 47--1820 days). Best clinical responses were SD (*n* = 12), progressive disease (*n* = 2), and unknown (*n* = 1).

In this study, there was no significant difference in either cell surface markers or inflammatory cytokines between before and after PPV. This could be mainly due to small numbers of patients with various types of cancers. These results, however, were partly similar to the previous cell surface marker study in which PPV induced increases and decreased the frequency of PD1^+^CD4^+^ T cells and that of PD1^+^CD8^+^ T cells in association with favorable overall survival.[@b25]

In summary, this study showed that PPV with these four different CTL epitope peptides could be feasible for HLA-A26^+^ advanced cancer patients because of the safety of the regimens and high rates of immunological responses.
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